Italfarmaco

This phase 3 trial tests whether givinostat, an oral drug, can slow muscle decline in boys aged 9 to 18 with Duchenne muscular dystrophy who can no longer walk. Participants receive either givinostat or a placebo for 18 months. The main goal is to see if the drug helps maintain u…

This phase 3 trial compares the experimental drug givinostat to the standard drug hydroxyurea in 220 adults with high-risk polycythemia vera, a blood cancer that increases red blood cells and raises clot risk. The study measures how well each drug controls blood counts and spleen…

This study looks at the long-term safety and effects of the drug givinostat in people with Duchenne muscular dystrophy (DMD). It is open to those who have already taken part in a previous givinostat study. The goal is to track side effects and see how well the drug works over tim…